The Effect of Topical Pranoprofen 0.1% on the Clinical Evaluation and Conjunctival HLA-DR Expression in Dry Eyes

The Effect of Topical Pranoprofen 0.1% on the Clinical Evaluation and Conjunctival HLA-DR Expression in Dry Eyes. A Single-Site, Prospective Randomized, Clinical study.

Article specifications

This clinical trial was published in 2012 in journal of Cornea (IF 2017:2.010) by Chinese ophthalmologists. In this study the effect of topical pranoprofen 0.1% on the clinical evaluation and conjunctival human leukocyte antigen II (HLA-DR) expression in dry eyes was investigated. 60 Patients with dry eye syndrome were randomized to 2 groups of 30 patients: group 1 were treated with topical Pranoprofen 0.1% 4 times a day plus topical sodium hyaluronate 0.1% 4 times a day in both eyes. Group 2 were treated with topical sodium hyaluronate 0.1% 4 times a day in both eyes without any other medicine. Ocular surface disease index (OSDI), tear film break-up time (TBUT), Schirmer I test, ocular surface staining (OSS), and conjunctival HLA-DR expression were evaluated before treatment and at 15 and 30 days after treatment.

Results

This study showed that both hyaluronic acid and pranoprofen 0.1% are effective and decrease dry eye symptoms although Topical pranoprofen demonstrated a beneficial effect upon clinical signs, symptoms, and conjunctival epithelial cell HLA-DR biomarker expression. At the same time,there are still concerns with the long-term use of topical pranoprofen 0.1% for dry eye patients. Because the side effects of cumulative BAK exposure can occur in a delayed or nonspecific manner, care should be exercised to avoid long-term preservative-induced toxicity.